Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. ( (JP:4882) ) has provided an update.
Perseus Proteomics Inc. announced the completion of a clinical study report for its Phase I trial of PPMX-T003, an anti-transferrin receptor 1 antibody, in patients with polycythemia vera. The trial, which involved six subjects, demonstrated safety and indicated efficacy, with five subjects experiencing a 12-week period without the need for phlebotomy. The results have no impact on the company’s fiscal year 2025/3 business results.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. operates in the biotechnology industry, focusing on the development of therapeutic antibodies. The company is engaged in the research and development of innovative treatments, with a particular emphasis on addressing unmet medical needs.
YTD Price Performance: 28.29%
Average Trading Volume: 639,280
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen10.17B
See more data about 4882 stock on TipRanks’ Stock Analysis page.